Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
Authors
Keywords
Hepatocellular carcinoma, Sorafenib, Response, Biomarker, Prediction
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1186/s12885-018-4211-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
- (2016) Masatoshi Kudo et al. JOURNAL OF GASTROENTEROLOGY
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2015) M. Ikeda et al. CLINICAL CANCER RESEARCH
- Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion
- (2015) Nicolas Poté et al. JOURNAL OF HEPATOLOGY
- Liver cancer: Approaching a personalized care
- (2015) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition
- (2015) Jiang-feng Xu et al. JOURNAL OF HEPATOLOGY
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
- (2014) Rosalba D’Alessandro et al. BMC CANCER
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma
- (2014) Carmen Chak-Lui Wong et al. HEPATOLOGY
- Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma
- (2013) Giovanni Sitia et al. JOURNAL OF HEPATOLOGY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Tivantinib in hepatocellular carcinoma
- (2012) Jörg Trojan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tumor-platelet interaction in solid tumors
- (2012) Daniel Buergy et al. INTERNATIONAL JOURNAL OF CANCER
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Cancer biomarkers: selecting the right drug for the right patient
- (2012) Gary J. Kelloff et al. NATURE REVIEWS DRUG DISCOVERY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation
- (2011) Hyun-Mi Bae et al. BMC CANCER
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelets
- (2010) Shashank Jain et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Predictive biomarker validation in practice: lessons from real trials
- (2010) Sumithra J Mandrekar et al. Clinical Trials
- The platelet contribution to cancer progression
- (2010) N. M. BAMBACE et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2009) Amy G. Shah et al. Clinical Gastroenterology and Hepatology
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- (2009) R. M. Simon et al. JNCI-Journal of the National Cancer Institute
- Complete blood count reflects the degree of oesophageal varices and liver fibrosis in virus-related chronic liver disease patients
- (2009) J.-H. Lee et al. JOURNAL OF VIRAL HEPATITIS
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- The cancer biomarker problem
- (2008) Charles L. Sawyers NATURE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search